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1. Introduction 
Evolution is the unifying framework in biology and scales to all living systems. It is the 
central organizing concept to explain seemingly disparate biological phenomena; from the 
very small (individual molecules) to the very large (ecosystems), from the rise and spread of 
molecular variants to the behavior and body shapes of elephants. In recent times, our 
appreciation for evolution in medicine has gained momentum. Individuals have 
championed the cause, dedicated journals have emerged, and new books on the subject are 
frequently published (“The Evolution and Medicine Review” is an excellent web-based 
resource providing updated information on the subject, http://evmedreview.com). This 
union between evolution and medicine has already advanced our understanding of 
pathological processes (Maccullum, 2007, Nesse & Stearns, 2008).  
Drug development and therapeutic strategies are areas in which evolutionary principles 
may be particularly helpful. The avalanche of bioinformatic methods, genomic data and 
subsequent emergence of evolutionary genomics in the last few decades means that 
integrating these fields in drug design is now a possibility. Incorporating evolutionary 
information is not only helpful a posteriori when we may hope to understand why resistance 
to a particular compound emerged. It is also valuable a priori, to design more efficacious 
drugs, suggest potential resistance profiles and conceptualize novel treatment strategies. 
Many allopathic treatments, particularly those for chronic non-infectious diseases, relate to 
the manipulation of cellular functions within one individual’s lifespan, for example, 
developing a drug aimed at a particular cardiac disorder. In these instances, evolutionary 
biology may explain why a particular disease arose, the evolutionary relationships between 
genes in the animal model and human or which pathological processes should be targeted. 
From an evolutionary perspective populations of reproducing individuals are the material 
on which evolution acts. Adaptive and non-adaptive changes occur over successive 
generations, and infectious organisms and cancer are therefore the premier examples to 
illustrate the role of evolution in drug development. In the current age it is almost 
unthinkable that evolutionary theory, the only scientific framework for studying ultimate 
causality in biology, doesn’t already form the starting point for developing therapeutic 
interventions affecting evolving populations.  
Here we wish to illustrate the role of evolution in allopathic medicine. A brief overview of 
the typical drug development pipeline is provided, followed by a discussion of relevant 
evolutionary questions. We discuss in greater detail the molecular evolutionary processes 
impacting on the emergence of drug resistance and offer suggestions to limit the problem. 
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Finally, we discuss the rapidly growing areas of evolvability and multilevel selection and 
how these inform our understanding of therapeutic strategies. 
2. Drug discovery strategies  
A drug discovery pipeline is a complex, costly and lengthy process involving several 
discrete stages (Fig. 1). The median time for the development of a new drug is estimated at 
~13 years, with a potential cost upwards of ~1 billion US dollars (Paul et al., 2010). The 
funnel shape of the pipeline reflects the high failure rate between different stages and fewer 
than 1 in 50 projects deliver a drug to the market (Brown & Superti-Furga, 2003). In the last 
few years especially the number of new approved drugs has declined sharply despite an 
increase in research and development spending. Data from a survey of nine large 
pharmaceutical companies revealed that in 2010 only two new molecular entities from all 
these companies were approved by the FDA, a very poor return on their expenditure of 
approximately $60 billion dollars (Bunnage, 2011). Several strategies have recently been 
proposed to reduce the costs and improve the success rates, including closer cooperation 
between pharmaceutical companies and academia (Cressey, 2011, Frye et al., 2011); 
investigation of new uses for approved drugs (Littman, 2011); increased use of translational 
phenotypic assays (Swinney & Anthony, 2011); and improved target and lead selection 
(Brown & Superti-Furga, 2003, Bunnage, 2011). 
 
 
Fig. 1. The drug discovery funnel. 
Evolutionary considerations are critical at steps in bold italics. 
The availability of whole genome sequences, new discoveries regarding the molecular basis 
of disease, technological advances in target and lead validation, and high throughput 
screening strategies, provide exciting opportunities for drug discovery. However, 
translational research requires improved coordination and integration between different 
scientific disciplines to ensure a justified transition past key decision points in the drug 
development pipeline. In this regard, it is critical that evolutionary biologists participate in 
the process to ensure that fundamental evolutionary principles are taken into account, 
especially at the validation steps (Fig. 1), to reduce costs and attrition.  
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3. Evolutionary concepts relevant to drug design 
To understand the evolutionary pressures on a potential drug target and the homologous 
relationships between target genes in the human and the proposed animal model, a few 
basic concepts should be addressed (Box 1). The reader is referred elsewhere for further 
discussion of general concepts of molecular evolution (Li, 2006). 
 
 
Box 1. Orthology, paralogy and functional shifts. In the hypothetical phylogram an ancestral 
gene has been duplicated to give paralogous isoforms 1 and 2 in mouse (M), rat (R) and 
human (H). Speciation events gave rise to orthologues M1, R1 and H1 and orthologues M2, 
R2 and H2. In the mouse there has been a second duplication event giving rise to M2*. The 
finding that M2* is isolated on a long branch indicates a functional shift in this gene 
3.1 Orthology and paralogy 
Homologous genes share a common ancestry and depending on the events in their history 
are orthologous or paralogous (Box 1). Orthologues arise from speciation events; paralogues 
arise from gene duplication events and resolving these relationships is best done with 
phylogenetic reconstructions. A number of methods can be used to re-create phylogeny 
(Felsenstein, 2004) each with their own strengths and weaknesses, however, it should be 
borne in mind that phylogenetic reconstructions are not foolproof and may require 
significant interpretation and re-examination. Processes like concerted evolution, horizontal 
gene transfer and incongruent evolution cloud the picture (Felsenstein, 2004, Li, 2006). 
Nevertheless, establishing orthology and paralogy (as best one can) raises major questions 
and both are important for drug development and assessment of drug targets (Searls, 2003). 
Orthology informs one about the corresponding gene(s) in the animal model while 
paralogous relationships are often more important for identifying functional divergence. 
www.intechopen.com
 
Drug Discovery and Development – Present and Future 28
3.2 Evolutionary rates 
Related to the reconstruction of phylogenetic relationships is the determination of 
evolutionary rates and patterns. The simplest way of estimating the nature and intensity of 
the selective pressure is to quantify the ratio of non-synonymous to synonymous nucleotide 
substitutions in a coding sequence, corrected for opportunity, taking into account various 
features of sequence evolution such as transition/transversion ratios, base and codon biases, 
etc (Box 2) (some key references are Goldman & Yang, 1994, Hurst, 2002, Muse & Gaut, 
1994, Nei & Gojobori, 1986, Yang, 2006, Yang & Nielsen, 2000). The ratio (dN/dS or ω) reflects 
fitness advantages or disadvantages resulting from changes in the amino acid sequence. A 
ratio ω>1 indicates positive (diversifying or adaptive) selection; ω<1 is negative (purifying 
or stabilizing) selection. In positive selection non-synonymous mutations are more prevalent 
in extant sequences presumably because they confer a fitness advantage. Negative selection 
indicates a fitness cost to non-synonymous substitutions. Furthermore, the lower the ω 
value, the stronger the stabilizing pressure as fewer and fewer non-synonymous 
substitutions are tolerated. If there is no difference between dN and dS substitution rates 
(ω=1), the selective pressure is neither stabilizing nor diversifying and evolution is neutral. 
Examining the evolutionary pressures not only informs one about functional divergence; 
but guides the researcher in the selection of the target site. Briefly, sites that are fast evolving 
are typically poor drug targets, while structurally and functionally conserved sites are 
usually under purifying selection and make more suitable targets.  
 
 
Box 2. A model for codon evolution (Goldman & Yang, 1994, Muse & Gaut, 1994). 
Numerous methods are available to quantify evolutionary rates in nucleotide sequences. An 
extensively used approach is the maximum likelihood (ML) codon model for evolution. A 
simplified substitution rate matrix used by the ML method to estimate codon evolution is 
given (left). The matrix is used to statistically determine evolutionary pressures acting at 
individual codons: positive, negative or neutral evolution (see text for more discussion and 
references below).  This model determines the probability that codon i mutates to j in a 
specified time interval and accounts for the transition/transversion rate ratio (κ); the 
equilibrium frequency of codon j (πj); and the non-synonymous/synonymous rate ratio (ω). 
Qij = 0 if i and j differ at more than 1 position.  
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4. Evolution and target selection  
One of the major causes of attrition of a potential drug candidate is poor quality of the 
target. The critical steps of target selection and validation require greater emphasis and 
incorporation of additional evolutionary criteria to reduce subsequent failure.  
4.1 Has the target undergone functional divergence?  
Many genes of therapeutic interest have undergone expansion leading to functional 
redundancy. Targeting a specific protein isn’t helpful if there are other family members that 
are immune to the drug and at the same time take over the function of the target. 
To assess functional shifts, paralogy is a critical consideration. The reason is pleiotropy, 
which is often associated with paralogous genes. Pleiotropy occurs when a gene product has 
more than one function and can either precede gene duplications or result from duplication 
events where the duplicated gene is less constrained and free to evolve multiple functions. 
The impact of pleiotropy on drug discovery is apparent when one considers that in these 
situations, one must disentangle the compound’s effect on multiple pathways. A good 
example of gene duplications leading to pleiotropy and functional divergence is that of the 
caspase family. The ancestral metazoan caspase has undergone numerous gene duplications 
over time resulting in at least 11 human and 10 murine true caspase genes (Nedelcu, 2009, 
Uren et al., 2000, Wang & Gu, 2001). In humans, distinct clusters of caspases have been 
identified (Uren et al., 2000, Wang & Gu, 2001), which may be involved in evolutionarily 
related but biochemically distinct pathways of inflammation or apoptosis. It also seems 
likely that some of the caspase family members are implicated in both processes. These 
proteins are primarily involved in one of the processes but are pleiotropically linked to the 
other. Disentangling the role of individual caspases in the two pathways would be 
important for developing drugs targeting either inflammation or apoptosis. 
5. Evolution and hit validation 
The assessment of hit compounds often requires in vivo testing in animal models and an 
inappropriate choice of model is one of the reasons why an apparently promising lead 
compound fails during human clinical trials. Understanding the phylogenetic relationships 
between genes in the two systems is therefore an important initial step. 
5.1 What are the evolutionary relationships between genes in the model and target 
organisms?  
The biochemical and pharmacological findings in an experimental model organism cannot 
be extrapolated to another organism without understanding the evolutionary relationships 
between the target genes. This is because evolutionary rates and functional divergence 
between homologous genes in related organisms may vary. It is important; therefore, to 
establish at the very least the homologous relationships between the gene used in the 
experimental system and the proposed target gene in the human.  
Even a slightly improved understanding of orthologous gene differences between model 
and target species can have an impact on the progression of a compound with major 
implications for scientific and financial resources. However, while orthology tells us about 
the evolutionary relationships between genes in related organisms and suggests similar 
function, this is not guaranteed. A phylogram may reveal that a particular gene in the model 
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organism is orthologous to the gene in the target organism. Despite this orthologous 
relationship isolation of the gene on its own long branch indicates sequence divergence and 
a functional shift. This should alert the researcher to be wary of using that particular model 
as a basis for studying the biochemistry of the protein in the human target. In the example 
given in Box 1 a duplication event has led to genes M2 and M2* in the mouse. This 
duplication occurred after the speciation events giving rise to humans and rats and both M2 
and M2* are therefore orthologues of R2 and H2. However, the isolation of M2* on its own 
long branch strongly suggests functional divergence and it should not be used as a model 
for developing a drug compound targeted at H2. 
Molecular evolution of homologous proteins may vary along different lineages, which 
means that a protein may appear highly stable and conserved in one branch leading to 
humans, but under a different selective pressure in the experimental model animal. If this is 
not taken into account inappropriate models may be selected. A good example of this is the 
finding that leptin is associated with obesity in mice (Chen et al., 1996). The discovery was 
greeted with tremendous excitement since it implied that rodents could be used as a model 
organism for studying the pathogenesis of obesity in humans. However, it subsequently 
emerged that there is evidence for positive selection in leptin in primates (including 
humans) but not in rodents (Benner et al., 2000). This indicates adaptive evolution and a 
functional shift in leptin after the divergence of primates from rodents. Using the mouse 
therefore, as a model for understanding the biochemistry of the protein and its potential use 
as a drug target in humans is problematic.  
6. Harnessing evolution to minimize the emergence of resistance 
Drug resistance is an ever present threat that curtails the effective lifespan of a drug and has 
enormous financial implications for pharmaceutical companies. Resistance can develop very 
rapidly, for example, resistance to the anti-malaria drugs pyrimethamine and proguanil 
(Hyde, 2005) developed within a year of introducing the drug to the market. Similarly, 
chronic myeloid leukaemia (CML) cells have become refractory to treatment with tyrosine 
kinase inhibitors targeting the bcr-abl oncogenic protein, necessitating the development of 
second and third generation inhibitors (Kantarjian et al., 2008). It is therefore vital that 
evolutionary principles are applied to the key decision points in the drug development 
process relating to the validation of targets, hits and lead compounds to minimize the 
emergence of resistance. 
6.1 What is the possible evolutionary response to drug pressure?    
Evolution occurs by non-adaptive and adaptive (Darwinian) means. Non-adaptive 
evolution includes pleiotropic phenomena and genetic drift, or may appear non-adaptive at 
one level of selection and adaptive at another. Adaptive evolution occurs by natural 
selection and is more closely associated with the concept of fitness. For pharmacological 
interventions against infections and cancer to be effective, they are aimed at killing or at 
least inhibiting growth of infective organisms or cancer cells. This means they generally act 
on adaptive traits so that fitness is compromised. Targeting a non-adaptive trait such as the 
pleiotropic effects of paralogous genes discussed above may have a minimal effect on 
fitness, limiting the drug’s usefulness. Targeting fitness-related traits is important for a drug 
to be effective, but doing so induces a Darwinian response if there are any survivors 
following the treatment. Furthermore, the greater the fitness cost resulting from the drug 
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pressure the stronger the evolutionary response (Read et al., 2011), and it is usually a 
question of when, rather than if, resistant mutants will emerge. 
There is effectively a therapeutic trade-off. From the perspective of treatment efficacy, the 
trade-off is between maximizing the fitness cost to the target (infectious agent or cancer cell) 
and minimizing the undesirable evolutionary escape response. Of course, if the fitness cost 
is absolute and all individuals in the population of infective organisms or cancer cells are 
killed, there is no trade-off. This is the ideal situation; but often not the case. Unless there is 
complete cure, there will be a therapeutic trade-off. Optimizing this trade-off is seldom 
given any consideration and therapy results in a temporary hiatus in the disease. Eventually 
the most resistant mutants take over and, as indicated, the most aggressive therapies elicit 
the strongest escape response (Read et al., 2011). In addition, not only does therapy select the 
most virulent individuals, but the group level dynamic is disrupted, further intensifying the 
escape response. Studies in mice infected with the malaria parasite Plasmodium chabaudi 
found that more virulent clones are controlled by less virulent ones (Wargo et al., 2007). 
Treatment that failed to eradicate all clones allowed the more virulent ones to thrive leading 
to a more serious secondary relapse. Humans living in malaria endemic areas can be 
infected with over 15 genotypically distinct clones of P. falciparum (Juliano et al., 2010). If the 
mouse model study is extrapolated to humans, then aggressive chemotherapy may actually 
be harmful in the long-term. Instead, to optimize the therapeutic trade-off, it is suggested 
that the guiding principle should be to impose no more selection than is absolutely 
necessary (Read et al., 2011). This holds particular relevance for infections or malignancies 
where cure is unlikely and therapy is aimed more at disease management, for example, 
chronic leukaemias and infections like HIV.  
An understanding of the evolutionary constraints acting at the molecular level is not only 
helpful when predicting the intensity of the evolutionary response, but it is also important 
for identifying the appropriate target sites of a protein. 
6.2 Can we identify target sites with minimal risk for resistance? 
There are various computational approaches (see Yang, 1997 and later versions) to 
determine the selective pressures acting on whole genes, specific codons or on lineages in a 
phylogenetic tree. Whole genes are seldom under positive selection; however, those that are, 
rapidly escape the fitness cost associated with the drug therapy. Non-synonymous 
substitutions already confer a fitness advantage in sequences demonstrating positive 
selection and the added drug pressure rapidly leads to resistance. To obtain a more 
informative view of a gene’s evolutionary rate, it is helpful to examine substitution rates at 
individual codons in the coding sequence. Maximum likelihood estimates of ω at individual 
codons will usually reveal variation across the coding sequence. Highly conserved or 
functionally important amino acids are likely to be under purifying selection, while others 
in the sequence may be evolving neutrally or be under positive selection. Targeting the 
positively selected or neutral sites will drive the emergence of resistance mutations and 
should be avoided, while sites under intense purifying selective pressures are far less likely 
to produce viable mutations and make suitable targets. 
Drug treatments add to the naturally occurring selective pressures and codon sites that code 
for resistant mutations are frequently evolving more rapidly than others. A good example of 
this is a study of serially sampled reverse transcriptase coding sequences isolated from a 
group of HIV-1 subtype C–infected women before and after single-dose nevirapine (Seoighe 
et al., 2007). Nevirapine is a standard therapy for preventing mother-to-child transmission. A 
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directional selection evolutionary model differentiated codons under positive selection from 
those subject to purifying selection and the differences in evolutionary rates would reliably 
have predicted a priori the sites of amino acid change leading to nevirapine resistance. This 
study provided proof of concept that quantifying the evolutionary pressures acting at 
individual codon sites can predict the likelihood of resistance emerging if the drug-protein 
binding site is known. Even before this study, others developed iterative approaches for use 
in development pipelines to guide experimentalists to biologically relevant sites based on 
sequence conservation. The first approach known as Evolutionary Tracing (ET) (Lichtarge et 
al., 1996, Lichtarge & Sowa, 2002) and another, Evolutionary Patterning (EP) (Durand et al., 
2008), which directly quantifies the evolutionary rate, provide useful examples for further 
illustration. 
6.2.1 Evolutionary tracing 
ET generates a trace sequence from multiple sequence alignments of functional classes of a 
protein family. Clusters of invariant amino acids are identified and incorporated into 3D 
structures to identify the most suitable target sites in terms of their conservation, functional 
and structural importance and access. ET is particularly helpful for modeling functional 
specificity and architecture-defining residues. ET predictions have been verified 
experimentally. The most complete demonstration that ET anticipates mutational and 
crystallographic analyses was performed on the regulator of G protein signaling proteins 
that act to increase Gα GTP hydrolysis rates (Sowa et al., 2000). Based on the ET data specific 
amino acids were mutated causing profound effects on enzyme activity and led to the 
prediction of an allosteric binding site (Sowa et al., 2001), which was subsequently confirmed 
by crystallography (Slep et al., 2001).  
6.2.2 Evolutionary patterning 
In ET, one of the premises for identifying target sites is that structurally and functionally 
essential amino acids are conserved in a trace sequence. However, while conservation 
suggests purifying selection it does not necessarily equate to it. To more accurately 
quantify the selective pressure acting at a particular amino acid residue, it is important to 
study the substitution rates at individual codons across a coding sequence. This is the 
approach adopted by EP, which makes use of a maximum likelihood substitution matrix 
to estimate the ratio of non-synonymous / synonymous substitutions at individual 
codons in a coding sequence (Box 2). The Bayes Empirical Bayes posterior probability of 
the MLE (maximum likelihood estimate) of ω falling into a particular category (for 
example, positive selection ω>1 or extreme purifying selection ω<0.1) is computed using 
PAML software (Yang, 2007). The distribution of these probabilities across a potential 
target protein can be examined and mapped to the predicted 3D structure, guiding the 
researcher as to which residues to target and which to avoid. It is argued that codons 
subject to extreme purifying selection are evolutionarily constrained, perhaps because the 
amino acid is essential for protein structure or function. The data from extant sequences 
indicate that non-synonymous mutations at these sites are not tolerated and make ideal 
drug targets if the encoded amino acids are accessible to interactions with lead 
compounds. In contrast, residues that are subject to positive or neutral selection, or only 
weakly conserved should be avoided. Non-synonymous mutations at these sites have 
arisen naturally during the evolutionary history of the protein indicating that amino acid 
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changes do not significantly compromise protein fitness. These sites should not be 
targeted therapeutically as any mutants that arise are likely to be selected for by the drug 
pressure. Mapping the amino acids under extreme purifying selection to a structural 
model is important so that the accessibility and interaction between target sites and lead 
compounds can be assessed in silico. As with ET, this is an iterative process. Docking 
studies uncover drug-protein interactions and the strength of chemical bonds assessed; 
interactions with undesirable amino acids are revealed and the lead compound may be 
modified so that contacts with target sites are optimized. The process can then be repeated 
as often as necessary to maximize favourable interactions.  
The application of EP to a potential drug target, P. falciparum glycerol kinase may be used as 
an illustration (Figures 2 and 3) (Durand et al., 2008). Six separate target sites comprising 
stretches of contiguous amino acids subject to extreme purifying selection were identified. 
The targets were mapped to a 3D model generated using the E. coli homologue as a 
template, which revealed that four were accessible to potential lead compounds. These sites 
were also found to overlap with functional domains and were suggested as therapeutic 
targets. The EP approach was validated by examining resistance mutations in the P. 
falciparum dihydrofolate reductase-thymidylate synthase protein, which is targeted by the 
anti-malarial drug pyrimethamine. EP predicted that none of the five known mutations 
conferring pyrimethamine resistance would have been subject to extreme purifying 
selection - a factor which would have facilitated the evolution of resistance. This was indeed 
the case, confirming that the likelihood of an evolutionary escape response was greater if the 
codon was under more relaxed evolutionary constraints. 
 
 
Fig. 2. Posterior probabilities for four categories of ω across GK coding sequences (from 
Durand et al., 2008). Bayes Empirical Bayes posterior probability estimates for each category 
of ω across P. falciparum (PfGK) and human (HsGK) GK coding sequences are shown. 
Residues under extreme purifying selection (ω≤0.1) are potential drug target sites and were 
mapped to a 3D model to assess drug accessibility (Fig. 3). Categories for ω are indicated 
with coloured bars: yellow (ω>1.0), red (ω=1.0), white (0.1<ω<1.0), and blue (ω≤0.1). 
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Fig. 3. E. coli and P. falciparum glycerol kinase 3D models (from Durand et al., 2008). Ribbon 
models (with functional residues as sticks) of E. coli glycerol kinase (EcGK) (A) and P. 
falciparum glycerol kinase (PfGK) (B) are displayed. In EcGK, coloured residues are 
involved in binding to ADP (blue), Mg2+ (yellow), glycerol (red), FBP (fructose-bis-
phosphate) (orange) and IIAGLC (purple).   Alpha helices and ß sheets in the ATPase site 
(light green) and subunit interactions (aquamarine) are shown. The PfGK model is based on 
EcGK. Five regions were identified in Fig. 2 as good target sites and mapped to ribbon (C) 
and surface (D) models. One of the regions (black) is partly obscured and is in the core of the 
molecule, indicating the region would not be accessible to drug compounds. 
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ET and EP provide guidance for selecting the most suitable drug target sites and thus assist 
in designing more effective drugs, which may limit the emergence of resistance for long 
periods. However, any drug pressure will still invoke an evolutionary response, so at some 
point escape mutants are still likely to arise. A truly fundamental shift in the approach to 
allopathic therapies would involve strategies aimed at having evolution work in our favour 
rather than against us. Doing so is a major conceptual challenge.  
7. Evolvability and multilevel selection: Future avenues for drug research 
Basic science research into the fundamental nature of evolution has resulted in what some 
biologists think is tantamount to a paradigm shift. For a review of these advances see 
discussions around an “extended theory of evolution” (Danchin et al., 2011). Two areas in 
which evolutionary thinking has rapidly progressed are the concepts of evolvability and 
multilevel selection. Both have relevance for future drug development strategies.  
7.1 Evolvability 
Advances in evolution hold promise for exploiting under-appreciated biological phenomena 
in drug design. The eloquent statement “Not only has life evolved, but life has evolved to 
evolve” (Earl & Deem, 2004) implies that the genetically encoded propensity to adapt to 
environmental pressures (known as evolvability) is a selectable phenotype. The variation in 
response to changing environments confers heritable variation in fitness. It is argued 
therefore, that evolvability can be acted on by natural selection leading to populations of 
organisms that are more or less likely to adapt to environmental pressures. Experimental 
evolution studies using model organisms like Escherichia (Leroi et al., 1994) and 
Chlamydomonas (Bell & Reboud, 1997) date back nearly two decades and seem to support 
these assertions although whether evolvability itself is always adaptive (as opposed to being 
non-adaptive) is not always clear (Creavin, 2004). Evolvability also appears to play a role in 
pathogen virulence. For example, the HIV reverse transcriptase (RT) is notoriously error-
prone leading to the evolution of populations of quasispecies that evade host immunity and 
escape drug pressures (Bebenek et al., 1993). However, as indicated above, whether the error 
prone nature of HIV RT evolved as an adaptation or whether it is the result of other 
adaptive or non-adaptive effects is uncertain. Nevertheless, what is clear is that the error 
rate of HIV RT confers a fitness advantage. Targeting the pathogen’s evolvability rather than 
phenotypic traits that are easily overcome by the propensity to evolve is therefore likely to 
have a greater impact in the long term. It can be argued that where evolvability forms part 
of a pathogen’s life history strategy, this consideration should be included in drug design 
efforts. For further discussion on plasticity and evolvability in parasitic infections such as 
malaria with relevance to chemotherapeutic strategies the reader is referred elsewhere (for 
example Reece et al., 2009). 
7.2 Multilevel selection theory 
7.2.1 Multilevel selection, sociobiology and the conceptualization of novel drug 
strategies 
Our understanding of the living world has been transformed by the finding that natural 
selection acts at multiple levels of biological organization (Box 3). Multilevel selection theory 
(MLST), which includes group selection and for which there is now a significant body of 
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evidence, describes the living world in terms of hierarchically structured levels where the 
tenets of selection are applicable to evolutionary units across these levels (Keller, 1999, 
Lewontin, 1970, Okasha, 2006, Wilson, 1975). Evolutionary transitions gave rise to increasing 
complexity including groups of genes, which form genomes, which form cells, which form 
multicellular organisms, which may form social groups and so on (Maynard Smith & 
Száthmary, 1995). The fact that the units of evolution span levels of biological organization 
raises the question of whether it may be better to target other levels of organization such as 
groups rather than individual cancer cells or infectious organisms. 
 
 
Box 3. The multilevel selection paradigm. The living world is characterized by quantum 
leaps in organization and complexity. Early replicators cooperated to form genomes and 
cells, which formed a eukaryotic cell, multicellular life, social groups and so on. Evolution 
by natural selection acts on any system where there is a group of reproducing individuals, 
so long as there is heritable variation in fitness. All these levels are therefore subject to 
natural selection. The related concept of group selection fits into this framework of MLST 
and describes competition between rather than within groups. While there is ongoing 
debate regarding the mechanisms, terminology and extent of group selection most 
researchers accept the fundamentals. 
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For drug development strategists, there are some key aspects to MLST that must be 
appreciated. Group level traits and adaptations arise because of selection and dynamics 
between groups rather than individuals within a group. These traits arise in various ways. 
They can be aggregates of properties within the group or arise as irreducible ‘emergent 
properties’ only existing at the group level (Thompson, 2000). Selection pressures at 
different levels of organization can vary; a particular trait can be beneficial at one level and 
harmful at another (see programmed cell death later) or the trait may have differential 
fitness benefits at two or more levels. Unpacking the relative selection pressures at different 
levels requires an understanding of Fisher’s fundamental theorem of natural selection, 
which states that “the rate of increase in fitness of any organism at any time is equal to its genetic 
variance in fitness at that time” (Fisher, 1930). Fisher’s theorem is applicable at any level of 
organization, whether it is a population of groups or a population of cells. Drugs targeting 
more than one level of selection will therefore induce differential responses and the intensity 
of the evolutionary escape response will depend on fitness variances at the different levels. 
Targeting the group level, rather than individuals as is the conventional approach has 
distinct advantages for therapies against infections (Pepper, 2008) and cancer (Pepper et al., 
2009). The advantages typically concern the phenomenon of cooperation and the group 
fitness variance. 
The phenomena of cooperation and its more extreme form altruism are commonly found in 
groups of pathogens or cancer cells. Mechanistically, cooperation can take the form of 
“public goods” (Wessler et al., 2007), molecules that are produced by individuals but have a 
group level action. The quantity or quality of molecule produced by one of the individuals is 
of such a nature that it may have little or no direct benefit for the producer, but in 
combination with the molecular products from others results in a group level fitness-
enhancing trait. For example, in bacterial biofilms quorum-sensing molecules regulate cell 
division of individuals so that the group responds to challenges as a collective (Wessler et 
al., 2007). Similarly, in solid tumours angiogenic factors are produced by individual cells but 
only when sufficient quantities are produced by the group does neo-vascularization occur 
(Kerbel, 1991). Targeting public goods makes good evolutionary sense.  
Consider a situation where individuals (cancer cells or pathogens) secrete molecules that 
only have a group level benefit. There is initially no benefit for a mutant individual because 
the concentration of its molecular product is either too low or on its own cannot modify the 
group phenotype and increase group fitness. More likely, its mutant nature means that its 
role in the group network is compromised and group fitness is diminished. Unlike 
conventional therapies which actively select for resistance, there is no immediate fitness 
benefit to mutants and resistant individuals die along with others in the group or they are 
selected against. Of course, a larger clone of resistant cells may survive and reproduce, but 
from the outset and all else being equal, mutants have the same or lower fitness than 
susceptible cells and generally do not take over the population. This scenario is more than 
just conceptual. It is supported empirically. One of the most detailed illustrations comes 
from the 15 year old study of tumour neo-vascularization and drug resistance referred to 
above (Boehm et al., 1997, Kerbel, 1991).  
In solid tumours cancer cells eventually outgrow their nutrient supply. Angiogenesis factors 
are produced by the tumour leading to neo-vascularization and subsequent survival of the 
group. Cytotoxic cancer drugs create a powerful selective pressure and in the heterogeneous 
population of cancer cells resistance rapidly emerges. However, targeting the group level 
benefit with “anti-angiogenic therapy does not induce drug resistance” (Boehm et al., 1997). 
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This is because while the angiogenesis blocker is applied, resistant mutants do not produce 
sufficient angiogenesis factors for neo-vascularization to occur and they die along with 
others before reaching a critical mass.  
Similar strategies have been advocated or used for a number of infectious diseases with 
some success, including the escalating challenge of methicillin-resistant S. aureus (MRSA) 
(see Pepper, 2008 and references therein). S. aureus produces numerous virulence molecules 
that act at the group level and are required for establishing and maintaining infections. The 
prototypical public good example in S aureus is α–toxin, without which infections in animal 
models are unsustainable (Bhakdi & Tranum-Jensen, 1991). A literature survey suggests that 
an appropriate and current opportunity for using MLST in drug development is 
tuberculosis (TB). TB is one of the major global health challenges and with the emergence of 
multidrug resistant (MDR) and extreme drug resistant (XDR) strains the need for novel 
strategies has never been more urgent. Laboratory studies of the resuscitation promoting 
factors (rpfs) in Mycobacterium species indicate that these factors may be prime targets for 
group level chemotherapy (for a review of rpfs see Kana & Mizrahi, 2010). Knockout 
experiments suggest rpfs have a negligible role in individual cell fitness; however, at the 
group level they are important as virulence factors and for the resuscitation of latent 
infections.  
With regards to fitness variance and the rate of evolution, Fisher’s theorem bodes well for 
drug strategies targeting cooperation in groups. The fitness variance of the phenotype 
decreases as the cooperative behaviour increases and is shared equally within the group (for 
a detailed discussion see Price, 1972). When fitness variance is zero, the implication is that 
either all the individuals in the group receive the benefit of the public good or none at all. 
The evolutionary rate of the group level phenotype is therefore exceedingly slow, as is the 
likelihood of resistance developing. This is in contrast to the evolutionary rates when the 
unit of selection is the individual in the group. In these instances fitness variance is usually 
greater and resistance evolves more rapidly. The fundamental properties of evolutionary 
rates as they relate to fitness variance coupled with cooperation and group level traits opens 
a whole new avenue for drug development strategies.  
7.2.2 Multilevel selection and the intriguing case of programmed cell death 
The phenomenon of programmed cell death (PCD) in unicellular eukaryotes brings together 
many aspects discussed in this chapter. It provides a useful context for integrating 
homology, adaptations, evolutionary rates, evolvability and MLST as they relate to 
infections, cancer and drug development. Our discussion of PCD below is based on a few 
key papers and requires far more investigation, but as an example it illustrates how 
evolutionary thinking could lead to a radical shift in drug design. 
Programmed cell death (PCD), previously considered a hallmark of multicellularity, has 
been reported in all major lineages in unicellular eukaryotes and prokaryotes (see Table 1 in 
Nedelcu et al., 2011). From an evolutionary perspective (with implications for drug design in 
infections and cancer) the burning question has been: why would an organism actively kill 
itself? For an individual unicellular organism PCD has no fitness benefit and adaptive 
evolution cannot explain the phenomenon. Likely explanations are that it is either 
maladaptive pleiotropy or adaptive in a MLS context (i.e. at a group level). While strong 
arguments can be made for both scenarios (Nedelcu et al., 2011), laboratory evidence from 
two model organisms favour the hypothesis that PCD in unicells is adaptive for the group. 
In S. cerevisiae PCD-related aging assists re-growth in a related mutant subpopulation 
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(Fabrizio et al., 2004, Herker et al., 2004). A direct fitness-related experiment in C. reinhardtii 
demonstrated that molecules released by cells dying by PCD provide fitness benefits to 
others (Durand et al., 2011). Genomic studies have also revealed that many of the 
homologues for key protein domains involved in PCD are conserved across a wide range of 
organisms (for example Nedelcu, 2009), although there has been expansion of many of the 
gene families, particularly in vertebrates and plants as organism complexity evolved. As 
discussed in sections 3 and 4, an understanding of the evolutionary rates and relationships 
between homologues in model and target organisms will be helpful if expanded gene 
families in the PCD pathway are to be targeted therapeutically. 
S. cerevisiae and C. reinhardtii are already used as model organisms for a range of diseases 
including cancer (for example Fang & Umen, 2008). The genomic and empirical data for PCD 
as an adaptation in these organisms shed new light on PCD in human parasitic infections and 
cancer and can help explain some puzzling phenomena. With regards to parasitic disease, 
numerous organisms demonstrate PCD, including apicomplexa, stramenopiles, trichomonads, 
diplomonads, kinetoplastids and trypanosomatids (see Table 1 in Nedelcu et al., 2011 and 
references therein). The group effect of PCD in most of these organisms has not been studied; 
however, in Leishmania (a kinetoplastid) infections, PCD as a group level adaptation explains 
the counterintuitive finding that virulence is associated with PCD (Van Zandbergen et al., 
2006). If the infective inoculum contains a proportion of apoptotic (PCD) cells, the population 
has greater virulence and fitness. Removing the apoptotic forms diminishes disease severity. 
The interpretation is that apoptotic forms enhance group fitness, which is in keeping with the 
C. reinhardtii findings. Similar experiments have not been performed with cancer cells, but the 
role of apoptosis is not always clear. Tumour suppressor genes are usually mutated in cancer; 
however, the apoptosis pathway is malignant cells is frequently activated through the FAS 
ligand receptor. Curiously, the FAS ligand pathway can also promote tumour growth (Chen et 
al., 2010). Whether this is due to crosstalk between this pathway and another anti-apoptosis 
pathway is unclear. However, in light of the C. reinhardtii experiments (Durand et al., 2011) and 
that the essential pathology of cancer is atavism (regression to the ancestral unicellular state) 
(Davies & Lineweaver), is it possible that apoptosis in some cancers also provides benefits to 
other cells in the population? In a bizarre twist, can chemotherapy exacerbate a cancer or 
infection by inducing PCD in some cells, which then provide fitness benefits to others?  
8. Concluding remarks 
The potential role for evolutionary biology in drug design is vast and can be applied at 
various stages in the development process. The aim here is to provide the reader with an 
overview of evolutionary medicine, with specific reference to drug design and the 
emergence of resistance in infections and cancer. Some key concepts such as phylogenetic 
relationships and evolutionary rates are introduced to illustrate how evolutionary studies 
can predict the most suitable drug target sites in a protein and limit resistance. Perhaps the 
most exciting union between evolution and drug development is the future use of 
evolvability and multilevel selection, heralding a new era for therapeutic strategies.  
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